PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC
E. Lee,
M. Matasar,
R. Conlon,
K. Mody,
S. Fiset,
J. Graff
Affiliations
E. Lee
1 Compassionate Cancer Care Group, Fountain Valley
M. Matasar
2 Memorial Sloan Kettering Cancer Center, Montvale, United States of America
